Analysis Of Clinical Efficacy Of Malignant Glioma With Personalized Treatment

Objective:To analysis the clinical efficacy of radiotherapy alone and concurrent chemoradiotherapy of malignant glioma after operation.Methods:The retrospective study included ninty-nine cases of malignant glioma after operation performed in Neurosurgery Departments of Shandong Provincial Hospital from Oct 2008 to Sept 2009.A11 the 99 cases of patients were divided into two groups: radiotherapy alone group(48 cases) and concurrent chemoradiotherapy group(51 cases). All patients began routine postoperative radiation therapy in 20 days or so, make 2Gy/day, divided 30 times, totaling 60Gy of radiotherapy, sustained 42 days (except Saturday and Sunday).The concurrent chemoradiotherapy group perform the program for temozolomide 75mg/m2/day for 42 days simultaneously;then after four weeks, the group accept 6 cycles of temozolomide adjuvant therapy, the program is 200mg/m2/day, once daily for 5 days, then 23 days withdrawal, treatment may continue until disease progression, up to 2 years. To make a statistics of 1,3,5-year survival rate of all cases,and to analysis the clinical efficacy of radiotherapy alone and concurrent chemoradiotherapy of malignant glioma after operation.Results:1,3,5-year survival rate of the radiotherapy alone group were 54.2%、29.2%、10.4 %, and the concurrent chemoradiotherapy group were 74.5%、51.0%、31.4 %, the concurrent chemoradiotherapy group was higher than the radiotherapy alone group(P<0.05). The concurrent chemoradiotherapy group had higher acute reaction such asnausea and vomiting, but bone marrow suppression, hearing loss, memory loss and other long-term damages were similar in the two groups.Conclusions:The concurrent chemoradiotherapy after malignant glioma operation may improve the outcome.